Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master protocol evaluating long-term safety of pirtobrutinib
CTR20252855Phase 4Active
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL), sponsored by Eli Lilly and Company. Started Aug 2025; status: active.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20252855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252855.